Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

BPC-157 for IBS Support: A Deep Dive for Researchers

Irritable Bowel Syndrome, or IBS, remains one of the most perplexing and debilitating gastrointestinal conditions impacting millions globally. It's a complex, often frustrating, cluster of symptoms that can severely diminish quality of life, ranging from relen

Irritable Bowel Syndrome, or IBS, remains one of the most perplexing and debilitating gastrointestinal conditions impacting millions globally. It's a complex, often frustrating, cluster of symptoms that can severely diminish quality of life, ranging from relentless abdominal pain and bloating to unpredictable bowel habits. For researchers and those in the scientific community, finding effective, targeted solutions for IBS support isn't just a clinical goal; it's a profound mission to alleviate widespread suffering.

Here at Real Peptides, our team is constantly immersed in the cutting-edge of peptide research, always looking for compounds with significant, sometimes dramatic, therapeutic potential. We've certainly noticed the escalating interest in BPC-157, particularly when it comes to its prospective role in gastrointestinal health. We're talking about a peptide that's garnering serious attention for its regenerative capacities, and its implications for IBS support are frankly, quite compelling. Let's really unpack what BPC-157 is, how it might offer a novel pathway for IBS support, and what researchers need to consider in 2026 and beyond.

Understanding the IBS Enigma: Why It's So Challenging

IBS isn't a single disease; it's a syndrome, a collection of symptoms without a clear, universally agreed-upon pathological cause. That's the core of the challenge, isn't it? Its multifactorial nature means it's influenced by everything from gut dysbiosis and visceral hypersensitivity to inflammation, altered gut motility, and even psychological stress. Current management strategies often focus on symptom alleviation—dietary modifications, probiotics, antispasmodics, or laxatives—but these rarely address the underlying, intricate physiological dysfunctions. They're often a patchwork, not a comprehensive solution. This is precisely why the scientific community, including our dedicated researchers, are scrutinizing every promising avenue, especially compounds like BPC-157 for IBS support.

We've seen countless studies in 2026 still grappling with the sheer heterogeneity of IBS patients. What works for one person might do absolutely nothing for another. This relentless variability demands research into compounds that offer broad-spectrum benefits, potentially hitting multiple targets simultaneously. That's where peptides, with their precise signaling capabilities, truly shine. Our collective experience has shown us that focusing on fundamental biological processes, rather than just surface-level symptoms, is the only way forward in such a formidable, often moving-target objective like IBS.

BPC-157: A Brief Overview of a Promising Peptide

BPC-157, or Body Protection Compound-157, is a synthetic peptide comprising 15 amino acids, derived from a protein naturally found in human gastric juice. It's not a new discovery, having been extensively studied for decades, but its diverse range of biological activities continues to astound researchers. Initially, it gained traction for its remarkable healing properties in various tissues, from tendons and ligaments to muscles and bones. We're talking about accelerated wound healing, anti-inflammatory effects, and even protective actions against organ damage. Our team at Real Peptides has always been fascinated by its pleiotropic effects, which means it influences multiple physiological systems.

But here's the critical point for today's discussion: its origin in gastric juice hints at a profound connection to the gastrointestinal system. It's naturally designed, it seems, to protect and repair the gut. This intrinsic link makes BPC-157 a standout candidate for investigating complex conditions like IBS. We've dedicated significant resources to understanding peptides of this caliber, ensuring that the BPC-157 10mg and BPC-157 Tablets we supply for research are of the highest purity and consistency, critical for reliable experimental outcomes. The fundamental question isn't if it impacts the gut, but how deeply and precisely it can offer BPC-157 for IBS support.

The Science Behind BPC-157 for IBS Support: Mechanisms of Action

When we talk about BPC-157 for IBS support, we're really delving into a fascinating array of biological mechanisms. It's not just one thing; it's a symphony of effects that could potentially restore gut homeostasis. Our researchers have identified several key pathways:

Anti-inflammatory Effects: Inflammation is a common, albeit not always overt, feature in many IBS presentations. BPC-157 has consistently demonstrated potent anti-inflammatory properties across various models. It modulates cytokine expression, effectively calming the inflammatory cascade that contributes to gut distress and pain. This alone is a monumental aspect of BPC-157 for IBS support.

Angiogenesis Promotion: This peptide is a master at promoting new blood vessel formation. Why is this important for IBS? A healthy blood supply is crucial for tissue repair and nutrient delivery, especially in a compromised gut lining. Enhanced microcirculation can help restore the integrity of the gut, which often suffers in IBS patients. It's comprehensive.

Epithelial Barrier Integrity: The 'leaky gut' hypothesis, while still debated, suggests that a compromised intestinal barrier allows toxins and undigested food particles to enter the bloodstream, triggering inflammation and immune responses. BPC-157 is known to strengthen the gut barrier, enhancing tight junctions and potentially reversing increased intestinal permeability. This is a critical, non-negotiable element of effective BPC-157 for IBS support.

Modulation of Neurotransmitters: The gut-brain axis is a well-established communication highway, and dysregulation here is a hallmark of IBS. BPC-157 interacts with several neurotransmitter systems, including the serotonergic and dopaminergic systems, which play pivotal roles in gut motility and pain perception. This complex interplay suggests a potential to rebalance the erratic signaling that defines IBS symptoms.

Growth Factor Induction: BPC-157 promotes the activity of various growth factors, such as VEGF (Vascular Endothelial Growth Factor) and FGF (Fibroblast Growth Factor), which are vital for tissue regeneration and repair. Think of it as providing the raw materials and signals for the body to heal itself, a powerful attribute when considering BPC-157 for IBS support.

Our professional observations confirm that this multi-pronged approach is what makes BPC-157 so intriguing. It doesn't just put a band-aid on symptoms; it appears to tackle several fundamental dysfunctions associated with IBS simultaneously. That's the reality. It all comes down to restoring balance.

Key Research Areas: How BPC-157 Interacts with Gut Physiology

Beyond its general mechanisms, specific research in 2026 is zooming in on how BPC-157 precisely influences the unique physiological landscape of the gut in the context of IBS. We've seen fascinating work exploring its impact on gut motility, which is notoriously erratic in IBS—sometimes too fast, sometimes too slow. Early studies suggest BPC-157 can normalize gut peristalsis, bringing it back to a more regular rhythm. This isn't just theory; it's been observed in various models, hinting at a profound regulatory effect.

Another crucial area involves visceral pain. People with IBS often experience heightened sensitivity to normal gut sensations, leading to excruciating pain from even minor distension. BPC-157 has shown analgesic properties, potentially reducing pain perception by modulating pain pathways in the gut and centrally. Our team believes this could be a game-changer for those suffering from chronic IBS pain, offering a pathway to genuine relief through BPC-157 for IBS support. We can't stress this enough: managing pain is a cornerstone of improving quality of life.

We're also keeping a close eye on research examining its effects on the gut microbiome. While BPC-157 isn't a probiotic, its ability to heal the gut lining and reduce inflammation could create a more hospitable environment for beneficial gut bacteria, indirectly fostering a healthier microbiome. This symbiotic relationship—BPC-157 helping the gut, and a healthier gut supporting overall well-being—is a nuanced and exciting avenue of inquiry for BPC-157 for IBS support.

Practical Considerations for Researchers: Sourcing and Purity

For any impactful research on BPC-157 for IBS support, the integrity of the peptide itself is paramount. This isn't just a recommendation; it's an absolute necessity. Compromised purity, inconsistent batches, or improper handling can invalidate entire studies, wasting precious time and resources. Our team at Real Peptides understands this intrinsically. We specialize in high-purity, research-grade peptides, crafted through small-batch synthesis with exact amino-acid sequencing. This guarantees the purity, consistency, and lab reliability that critical research demands. We've found that this meticulous approach delivers real results, allowing researchers to trust their inputs.

When you're exploring the intricacies of BPC-157 for IBS support, you need to be confident that your BPC-157 10mg or BPC-157 Tablets are precisely what they claim to be. This commitment extends across our full range, including specialized compounds like TB-500 (thymosin Beta-4) for comprehensive regenerative protocols. We don't just supply peptides; we supply peace of mind, knowing that the foundation of your research is solid. Our dedication to quality is unwavering, because we understand the profound impact your discoveries can have, particularly in complex areas like Gut Health Research.

Navigating Research Protocols: Comparing Approaches to BPC-157 Use

When designing studies for BPC-157 for IBS support, researchers face several protocol considerations. The choice of administration route, dosage, and duration can significantly impact experimental outcomes. Our collective experience highlights the importance of tailoring these variables to the specific research question. Anyway, here's what makes the difference. We often see researchers comparing different methods, each with its own advantages and challenges.

Ease of Use

Very easy, non-invasive

Requires training, sterile technique

Bioavailability

Generally good, site-specific

High systemic bioavailability

Targeting

Direct gut action, systemic

Systemic distribution, diffuse effects

Dosing Precision

Standardized dosage per tablet

Precise, adjustable liquid dosage

Stability

High stability in tablet form

Requires careful reconstitution, storage

Research Focus

Gut-specific issues, long-term

Systemic effects, acute interventions

Considerations

Gastric environment, absorption

Patient compliance, potential discomfort

Our team recommends careful consideration of these factors. For instance, if the primary research objective is to study localized gut barrier repair, oral BPC-157 Tablets might be a logical choice due to their direct passage through the GI tract. Conversely, for systemic anti-inflammatory effects that could also benefit IBS, injections of BPC-157 10mg might be preferred. It's about optimizing for the specific hypothesis, not a one-size-fits-all approach. This approach (which we've refined over years) delivers real results. We mean this sincerely: it runs on genuine connections and meticulous science.

The Future of Gut Health Research: BPC-157's Evolving Role

The landscape of gut health research is evolving at an unprecedented pace in 2026. We're seeing a shift from purely symptomatic treatments to more fundamental, regenerative approaches. BPC-157 for IBS support fits perfectly into this paradigm. Its ability to modulate inflammation, promote healing, and regulate gut function offers a holistic, rather than fragmented, approach to a condition that often defies simple solutions.

We anticipate further research into combination therapies, exploring how BPC-157 might synergize with other compounds or interventions. Imagine pairing it with targeted probiotics, or even with other peptides known for their gut-supportive properties, such as KPV or LL-37. The possibilities for creating a truly comprehensive Healing & Total Recovery Bundle are immense. This is where the true innovation lies, in understanding these complex interactions. Our team is always here to discuss potential research avenues and provide the highest quality materials for these groundbreaking studies.

It's becoming increasingly challenging to ignore the growing body of evidence supporting BPC-157's multifaceted benefits. We're not just talking about academic curiosity; we're talking about real-world implications for improving digestive health and alleviating the grueling burden of IBS. The focus on BPC-157 for IBS support isn't just a fleeting trend; it's a robust, scientifically grounded pathway that deserves continued, rigorous investigation.

Real Peptides' Commitment to Advanced GI Research

At Real Peptides, our mission extends beyond merely supplying high-purity peptides. We see ourselves as partners in scientific discovery. We understand the demanding schedules and high expectations that come with cutting-edge research. That's why we meticulously synthesize our peptides in small batches, guaranteeing exact amino-acid sequencing and unparalleled purity. This commitment ensures that when you're exploring the nuanced potential of BPC-157 for IBS support, you're working with the most reliable materials available.

Our dedication to quality and consistency is why researchers trust us for their most critical studies. From foundational BPC-157 10mg to an extensive array of other compounds, we're here to fuel the breakthroughs of tomorrow. We believe that by providing superior research tools, we're contributing to a future where conditions like IBS are better understood and, ultimately, more effectively managed. We encourage you to explore our full range of peptides and discover how Real Peptides can support your next ground-breaking study.

The journey to unraveling the complexities of IBS is a long and arduous one, but with powerful compounds like BPC-157 emerging as significant contenders for effective IBS support, there's a tangible sense of hope. The collective efforts of dedicated researchers, armed with high-quality, reliable peptides, are steadily paving the way toward a future where digestive wellness is not just an aspiration, but a widespread reality. We're incredibly excited to be a part of that journey, supplying the critical components that make such discoveries possible, pushing the boundaries of what we thought achievable in gut health research. It's a remarkable time to be in this field, and we're ready for what comes next. Join us in shaping that future; Explore High-Purity Research Peptides with confidence.

Frequently Asked Questions

BPC-157 is a synthetic peptide derived from a naturally occurring protein in human gastric juice. Its relevance for IBS support stems from its potent anti-inflammatory, regenerative, and gut-protective properties. It’s believed to help restore gut integrity and function, which are often compromised in IBS.

BPC-157 is known to strengthen the intestinal epithelial barrier. It enhances the tight junctions between gut cells, which can reduce ‘leaky gut’ syndrome often associated with IBS. This action helps prevent unwanted substances from entering the bloodstream, thus potentially reducing inflammation and discomfort.

Yes, BPC-157 modulates various inflammatory pathways, reducing the production of pro-inflammatory cytokines. This calming effect on gut inflammation is crucial, as even low-grade inflammation can contribute significantly to IBS symptoms like pain and altered bowel habits. Our team finds this a key area of study for BPC-157 for IBS support.

Research suggests BPC-157 can help normalize erratic gut motility, a common issue in IBS. It appears to regulate peristalsis, potentially alleviating both diarrhea and constipation components of the syndrome. This rebalancing effect is a significant area of interest for researchers.

Research protocols vary, but both oral (e.g., [BPC-157 Tablets](https://www.realpeptides.co/products/bpc-157-capsules/)) and injectable forms (e.g., [BPC-157 10mg](https://www.realpeptides.co/products/bpc-157-peptide/)) are commonly studied. Dosages are typically low, in the microgram range, and tailored to the specific research model and desired systemic or localized effects. Researchers should always consult established protocols.

At Real Peptides, we prioritize purity and consistency above all else. Our [BPC-157 10mg](https://www.realpeptides.co/products/bpc-157-peptide/) and [BPC-157 Tablets](https://www.realpeptides.co/products/bpc-157-capsules/) are crafted through small-batch synthesis with exact amino-acid sequencing. This rigorous process guarantees the high purity and reliability essential for credible scientific research, which is paramount for studies involving BPC-157 for IBS support.

Yes, BPC-157 is believed to interact with various neurotransmitter systems, including serotonin and dopamine, which are integral to the gut-brain axis. Modulating these pathways could help alleviate visceral hypersensitivity and pain perception, crucial aspects of IBS. This connection highlights its potential for comprehensive IBS support.

As with any research compound, adherence to strict laboratory protocols and ethical guidelines is essential. While BPC-157 is generally considered well-tolerated in animal studies, researchers should always conduct thorough risk assessments. Our team recommends careful handling and proper storage of all peptides.

BPC-157 stands out due to its unique origin in gastric juice and its broad spectrum of regenerative effects specifically on the GI tract. While other peptides like [TB-500 (thymosin Beta-4)](https://www.realpeptides.co/products/tb-500-thymosin-beta-4/) also have regenerative properties, BPC-157’s direct gut-protective actions make it particularly compelling for IBS support research. It’s often viewed as a primary peptide for digestive healing.

We anticipate further exploration into BPC-157’s synergistic effects with other compounds or probiotics. Research will likely delve deeper into its long-term impact on gut microbiome balance and its potential as a foundational component in comprehensive [Gut Health Research](https://www.realpeptides.co/collections/regeneration-recovery/) protocols. The focus on BPC-157 for IBS support will undoubtedly broaden.

No, it’s crucial to understand that BPC-157 is a research compound with promising potential for IBS support, not a definitive ‘cure.’ IBS is a complex syndrome, and while BPC-157 shows significant therapeutic promise in modulating its underlying mechanisms, it’s still undergoing extensive scientific investigation. We encourage researchers to view it as a powerful tool in understanding and potentially managing the condition.

Researchers can access high-purity, research-grade BPC-157 through reputable suppliers like Real Peptides. We ensure our [BPC-157 10mg](https://www.realpeptides.co/products/bpc-157-peptide/) and [BPC-157 Tablets](https://www.realpeptides.co/products/bpc-157-capsules/) meet stringent quality control standards. You can explore our full range of peptides and our commitment to scientific excellence on our website.

Yes, preliminary research indicates BPC-157 may possess analgesic properties, potentially reducing the heightened visceral pain often experienced by individuals with IBS. Its modulatory effects on pain pathways in the gut are a key area of ongoing study, offering a promising avenue for pain relief in IBS support. This is a significant finding.

Purity is absolutely critical because even minor impurities can introduce confounding variables into experimental results, leading to inaccurate conclusions. High-purity peptides ensure that observed effects are genuinely attributable to BPC-157, making research outcomes reliable and reproducible. Our team at Real Peptides guarantees this level of precision for all our research compounds.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

BPC-157 Animal Research: Dosage and Administration Routes

BPC-157 animal research consistently uses doses ranging from 10 micrograms per kilogram to 10 milligrams per kilogram, with most studies clustering around 10–100 micrograms per kilogram delivered once or twice daily. These doses are not recommendations for human use—they're experimental parameters designed to establish dose-response relationships and identify minimum effective concentrations. A 2017 dose-response study in rats found that 10 micrograms per kilogram intraperitoneally was sufficient to produce measurable healing acceleration in gastric ulcer models, while 1 microgram per kilogram showed no significant effect, and 100 micrograms per kilogram produced no additional benefit beyond the 10 microgram dose—establishing a clear therapeutic window. Administration routes in BPC-157 animal research include intraperitoneal injection (most common), subcutaneous injection, intramuscular injection, oral gavage, and topical application, with route selection dictated by injury location and research question. Systemic routes (intraperitoneal, subcutaneous) are used when studying distant injury sites or whole-body effects, while local injection directly into injured tissue is used to achieve higher concentrations at the repair site. Interestingly, oral administration shows efficacy in gastrointestinal injury models despite the peptide being a 15-amino-acid chain that would normally be degraded by digestive enzymes—this suggests either partial stability or sufficient mucosal absor…
STORAGE

Storage and Reconstitution Requirements for Joint Research Protocols

BPC-157 is supplied as lyophilized powder and must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, the solution remains stable at 2–8°C (standard refrigeration) for up to 28 days, though some research groups use it within 14 days to minimize degradation. Temperature excursions above 8°C denature the peptide irreversibly. A single overnight incident at room temperature renders the vial unusable, even if it appears visually unchanged. Unlike larger proteins, BPC-157's 15-amino-acid chain is vulnerable to oxidation; antioxidant-free bacteriostatic water (0.9% benzyl alcohol in sterile water) is the standard reconstitution vehicle. Cartalax stability depends on formulation. Oral capsules can be stored at room temperature (15–25°C) in a sealed container away from moisture. Injectable Cartalax follows the same lyophilized storage rules as BPC-157: −20°C before reconstitution, 2–8°C after mixing, use within 28 days. Because Cartalax is a tetrapeptide (even shorter than BPC-157), it's more susceptible to hydrolysis. Some researchers prepare single-use vials rather than multi-dose vials to avoid repeated punctures that introduce air and potential contaminants. Reconstitution errors are the most common failure point in peptide research. Inject bacteriostatic water slowly down the side of the vial. Never directly onto the powder. To prevent foaming and peptide aggregation. Swirl gently; do not shake. Let the vial sit for 60–90 seconds to fully dissolve b…
02

Question drills

Open a question for its connected answer.

01What If I Try BPC-157 for SIBO Without Addressing the Root Cause?+

BPC-157 won't eradicate bacterial overgrowth if the underlying motility disorder, anatomical obstruction, or immune deficiency remains untreated. SIBO recurs in 40–45% of patients within 9 months after rifaximin precisely because the predisposing factor wasn't corrected. If you're considering BPC-157 studied SIBO protocols, identify your SIBO subtype first. Hydrogen-dominant (from carbohydrate fermentation), methane-dominant (from Methanobrevibacter overgrowth), or hydrogen sulfide-dominant. Each requires different antimicrobial strategies, and BPC-157's mucosal repair effects won't compensate for persistent bacterial replication if motility remains impaired.

SOURCE / realpeptides.co ↗
02What If I’m Comparing BPC-157 Suppliers in Colorado — What Should I Verify First?+

Before purchasing BPC-157 in Denver or anywhere in Colorado, request the Certificate of Analysis for the specific lot you’ll receive. Not a generic sample COA from six months ago. The COA should specify purity above 98% via HPLC, confirm molecular weight via mass spectrometry, and be dated within 90 days. Real Peptides includes lot-specific COAs with every Denver shipment and publishes third-party lab names, not in-house testing. A supplier unwilling to provide the actual COA before purchase is a reliability risk.

SOURCE / realpeptides.co ↗
03What if my research timeline in Raleigh requires expedited shipping?+

Orders placed before 2 PM EST ship same-day from our fulfillment center, with standard delivery to Raleigh addresses in 2-4 business days via USPS Priority. Expedited overnight shipping to NC is available at checkout for time-sensitive research protocols. All peptides ship in insulated packaging with gel packs to maintain cold-chain integrity during transit, critical for peptide stability in North Carolina’s variable climate.

SOURCE / realpeptides.co ↗
04What If I've Tried L-Glutamine and Probiotics Without Improvement?+

L-glutamine supports enterocyte metabolism but doesn't directly upregulate tight junction genes. Probiotics modulate microbial balance but take 6–12 weeks to show structural effects. If you've addressed inflammation and microbiome imbalance without measurable permeability improvement, the issue is likely at the tight junction protein level itself. The bpc-157 intestinal permeability mechanism targets that directly: it increases occludin and ZO-1 transcription regardless of microbial composition or substrate availability. Consider a 4–6 week trial at research-grade doses (200–500 μg daily subcutaneously for a 70kg individual, extrapolated from rodent mg/kg dosing) while maintaining glutamine and probiotic use. The peptide addresses a different mechanistic layer.

SOURCE / realpeptides.co ↗
05What If I Inject BPC-157 and LL-37 at the Same Time — Does It Still Work?+

Yes, but at significantly reduced efficacy. Co-injection produces outcomes closer to BPC-157 monotherapy because LL-37's peak plasma concentration occurs before BPC-157's angiogenic effects manifest. The immune cells LL-37 recruits arrive at tissue that hasn't yet developed the vascular capacity to deliver them to the injury core. A rat Achilles tendon study found simultaneous injection produced 28% improvement in tensile strength versus 62% with 90-minute sequential dosing. The peptides don't neutralise each other. They simply fail to compound because their mechanisms require temporal layering.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Importance of Research-Only Classification

BPC-157 is not approved for human or veterinary use by regulatory authorities. Any discussion of the compound should remain within the scope of: Laboratory research Analytical testing Academic study Responsible suppliers and researchers treat BPC-157 strictly as a research material, handled and stored according to standard laboratory protocols.

RESEARCH

Navigating the Research Landscape: Important Considerations for 2026

As we forge ahead into 2026, the landscape of peptide research continues its rapid evolution. Understanding what is Body Protection Compound 157 within this dynamic environment requires a keen eye on emerging trends and regulatory discussions. The scientific community is becoming increasingly sophisticated in its methodologies, demanding higher standards for experimental design and data interpretation. This means that researchers need to be more diligent than ever in their protocols. One significant trend we're observing is the move towards multi-compound research protocols. Researchers aren't just looking at what is Body Protection Compound 157 in isolation anymore. They're exploring synergistic effects by combining it with other peptides, perhaps for enhanced regenerative outcomes. For example, pairing BPC-157 with TB-500 (thymosin Beta-4) is a common strategy in studies aiming for comprehensive tissue repair. This holistic approach is gaining considerable traction, reflecting a deeper understanding of biological complexity. We've even developed bundles like our Healing & Total Recovery Bundle specifically to support such comprehensive research designs. Another critical consideration is the ethical framework surrounding peptide research. As the public's awareness of compounds like BPC-157 grows, so too does the scrutiny. Responsible research practices, clear communication of findings, and adherence to all relevant guidelines are absolutely paramount. We believe in fostering a community where knowledge is shared ethically and transparently. Our commitment to providing only research-grade materials underscores this dedication. When you're exploring what is Body Protection Compound 157, remember that the integrity of the science extends far beyond the lab bench.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Local Versus Systemic Delivery Research

The BPC-157 throat spray format raises an important research distinction: local versus systemic delivery. Local delivery — which a throat spray provides to the oropharyngeal and u…

Comparison

The Oral vs Injectable Efficacy Gap No One Explains

Oral BPC-157 capsules are marketed at price points 20–35% lower than injectable forms. And they deliver proportionally lower bioavailability. The peptide's molecular weight (1419 …